<DOC>
	<DOCNO>NCT00562523</DOCNO>
	<brief_summary>The purpose study : 1 . ) Evaluate body react sorafenib take daily ( continuously ) combination docetaxel give every 3 week , determine safety two drug together.2 . ) Measure blood level sorafenib docetaxel specific time take medication .</brief_summary>
	<brief_title>Sorafenib/Docetaxel Dose Escalation Trial</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age great equal 18 year Advanced histological cytological documentation cancer At least one evaluable lesion ECOG Performance Status 0 1 No one prior chemotherapy regimen ( prior adjuvant therapy , immunotherapy hormone treatment allow restrict ) Life expectancy least 12 week No previous exposure docetaxel sorafenib Adequate bone marrow , liver renal function assess follow : Hemoglobin great equal 9.0 g/dL Absolute neutrophil count ( ANC ) great equal 2,500/mm3 Platelet count great equal 100,000/mm3 Hepatic Total Bilirubin less equal ULN AST , ALT Alkaline Phosphatase le 1.5x ULN . PTINR/PTT le 1.5 x ULN ( Patients prophylactically anti coagulate agent coumadin heparin allow participate provide INR le 1.5 . In addition , patient must monitor appropriate interval throughout study ) Serum creatinine less equal 1.5 x upper limit normal Myocardial infarction symptomatic coronary artery disease ( severe unstable angina ) within 6 month prior screen Active clinically serious infection ( &gt; Grade 2 NCICTCAE Version 3.0 ) Uncontrolled seizure disorder . Use cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine phenobarbital ) allow Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Known human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Peripheral neuropathy &gt; Grade 1 Thrombotic embolic event ( transient ischemic attack , myocardial infarction , pulmonary embolus ) , within 6 month prior screen Major surgery , open biopsy significant traumatic injury within 4 week first study treatment Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Sorafenib</keyword>
</DOC>